ABT 627. A 147627, ABT 147627.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000077868:Atrasentan; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003327:Coronary Disease / Q000188:drug therapy; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011759:Pyrrolidines / Q000494:pharmacology* / Q000627:therapeutic use
D015507:Drugs, Investigational; D065128:Endothelin Receptor Antagonists; D011759:Pyrrolidines; D000077868:Atrasentan